Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency
Stock Information for Arcturus Therapeutics Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.